Jiawei Erzhiwan Ameliorates Androgenetic Alopecia by Regulating the SIRT1/JNK/p38 MAPK Pathway
Drug Design, Development and Therapy · 2025-04 · Volume 19 · 2393-2409
DOI: 10.2147/dddt.s501823 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-04. Verfasst von Zhiguang Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Alopecia, Phytochemicals, Plant Extracts. Die Arbeit wurde bisher 10-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
Androgenetic alopecia (AGA) is a type of hair loss. Our previous study showed AGA ameliorating capability of water extract of an herbal prescription, "Jiawei Erzhiwan" (WJWE), which was derived from the traditional formula "Erzhiwan". However, the underlying mechanisms is still unknown. Patients and Methods: In this study, the phytochemical ingredients in WJWE were characterized via UPLC‒MS/MS analysis. The dihydrotestosterone (DHT)-induced murine model and dermal papilla cells (DPCs) assays were used to evaluate and elucidate the beneficial effects and mechanisms of WJWE on AGA.
Results
WJWE promoted hair growth and hair follicle regeneration in AGA mice, improved DPCs growth and dose-dependently protected DHT-reduced DPCs viability in vitro by stimulating the Wnt5A/β-Catenin pathway. Additionally, WJWE reduced DHT-induced oxidative stress in AGA model murine skin and DHT-treated DPCs. To elucidate the regulative mechanism, we found that WJWE treatment significantly and dose-dependently increased the expression of SIRT1 and reduced the phosphorylation of JNK and p38 MAPK in both DHT-treated DPCs and AGA model mice. And the application of EX527 (a SIRT1 inhibitor) could the effect of WJWE.
Conclusion
Our study provided some evidence of WJWE on AGA treatment, by which SIRT1/JNK/p38 MAPK signaling pathway might be the major target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
- Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
- The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
- School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
- Jiaxing TCM Hospital Affiliated to Zhejiang Chinese Medical University, Jiaxing, People's Republic of China.
ORCID-Profile: Bin Ding
Zitieren
APA
Huang, Z., Li, Y., Xie, Y., Fu, H., Weng, Z., Yuan, J., Wu, L., Lin, W., Cao, Y., & Ding, B. (2025). Jiawei Erzhiwan Ameliorates Androgenetic Alopecia by Regulating the SIRT1/JNK/p38 MAPK Pathway. Drug Design, Development and Therapy, Volume 19, 2393-2409. https://doi.org/10.2147/dddt.s501823
Vancouver
Huang Z, Li Y, Xie Y, Fu H, Weng Z, Yuan J, et al. Jiawei Erzhiwan Ameliorates Androgenetic Alopecia by Regulating the SIRT1/JNK/p38 MAPK Pathway. Drug Design, Development and Therapy. 2025;Volume 19:2393-2409. doi:10.2147/dddt.s501823
BibTeX
@article{Huang2025,
author = {Huang, Zhiguang and Li, Yuanyuan and Xie, Yixin and Fu, Hangjie and Weng, Zhiwei and Yuan, Jianchang and Wu, Lan and Lin, Weizhou and Cao, Yi and Ding, Bin},
title = {Jiawei Erzhiwan Ameliorates Androgenetic Alopecia by Regulating the SIRT1/JNK/p38 MAPK Pathway},
journal = {Drug Design, Development and Therapy},
year = {2025},
volume = {Volume 19},
pages = {2393--2409},
doi = {10.2147/dddt.s501823}
}
EUVIMED